Marianne E. Yassa

Dr. Marianne E. Yassa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Life Sciences
Verified
Journal Article
Closed access
MYMarianne E. Yassa
Marianne E. Yassa
IMIman A. Mansour
Iman A. Mansour
NSNadia I. Sewelam
Nadia I. Sewelam
HHHala Hamza
Hala Hamza
TGTaghrid Gaafar
Taghrid Gaafar

8 June 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
MBMohammad Barouqa
Mohammad Barouqa
MAMuhammad Areeb Ashfaq
Muhammad Areeb Ashfaq
KJKatrina J. Jiang
Katrina J. Jiang
HKHuseyin Kilic
Huseyin Kilic
NCNestor Dela Cruz
Nestor Dela Cruz
MYMarianne E. Yassa
Marianne E. Yassa
Background/Objectives: The Duffy (Fy) blood group system, encoded by the ACKR1 gene, plays a key role in transfusion medicine and host susceptibility to malarial infections such as Plasmodium vivax. The Duffy-null phenotype [Fy(a−b−)] is associated with lower baseline white blood cell (WBC) and absolute neutrophil count (ANC) values despite a benign clinical course. This study aimed to establish specific reference intervals for WBC and ANC in Duffy-null individuals to improve diagnostic accuracy and reduce unnecessary clinical interventions. Methods: We conducted a retrospective analysis of 1695 adult patients who underwent complete blood count testing and red blood cell phenotyping between 1 January 2020 and 1 January 2026. Among these, 122 healthy individuals with confirmed Fy(a−b−) phenotype met inclusion criteria. Reference intervals were established using 95% reference interval nonparametric methods in accordance with Clinical Laboratory Standards Institute (CLSI) guidelines. Results: The median WBC and ANC values in the Duffy-null cohort were significantly lower than institutional reference medians (3.24 vs. 6.65 × 103/µL and 1.45 vs. 4.45 × 103/µL, respectively; p < 0.01). The derived 95% reference intervals (WBC: 2.43–7.05 × 103/µL; ANC: 1.01–4.34 × 103/µL) fell below conventional thresholds, with the lower ANC bound below the standard neutropenia cutoff. Conclusions: These findings support the need for Duffy-null-specific hematologic reference ranges. Adoption of such intervals may reduce misclassification, avoid unnecessary diagnostic procedures, and promote personalized clinical care.

8 March 2021 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
MYMarianne E. Yassa
Marianne E. Yassa
HAHanaa H. Arnaout
Hanaa H. Arnaout
SBShahira K. Botros
Shahira K. Botros
EOEmad N. Obaid
Emad N. Obaid
WMWael M. Mahmoud
Wael M. Mahmoud
DMDalia S. Morgan
Dalia S. Morgan
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Glutathione-S-methyl transferase (GSTs) enzymes’ family is known to catalyze carcinogens detoxification. Overexpression of (GSTO) omega class was reported in cancer occurrence. The purpose of the study was to investigate the association of GSTO1*A140D (rs4925) and GSTO2*N142D (rs156697) polymorphisms with the susceptibility to childhood ALL and to evaluate their prognostic impact. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism technique in 96 Egyptian pediatric ALL patients and 99 controls. Results: No statistically significant different GSTO1*A140D genotype and allele distribution was observed among ALL cases and controls; however, a statistically significant different GSTO1*A140D genotype distribution was found between de novo ALL cases and controls [CC (37% vs. 56.6%), CA (47.8% vs. 40.4%), and AA (15.2% vs. 3.0%), respectively] (0.008). GSTO1*A140D variant genotypes’ frequency was significantly higher in de novo cases than in controls (63% vs. 43.4%) (0.028). The minor allele frequency (MAF) of GSTO1*A140D-A was significantly higher in de novo cases compared to controls (0.39 vs. 0.23) (0.005). Genotyping of GSTO2*N142D revealed a statistically significant difference of genotype distribution between ALL patients and controls [AA (26% vs. 36.3%), AG (62.5% vs. 61.6%), and GG (11.4% vs. 2.0%), respectively] (0.017) and between de novo ALL cases and controls [AA (37% vs. 36.3%), AG (45.7% vs. 61.6%), and GG (17.3% vs. 2.0%), respectively] (0.002). The MAF of GSTO2*N142D-G was significantly higher in ALL patients than in controls (0.42 vs. 0.32) (0.046). The high-risk ALL group had a higher frequency of GSTO1*A140D and GSTO2*N142D variant genotypes compared to corresponding wild genotypes and a higher frequency of combined polymorphisms compared to single polymorphisms and wild genotypes but with no statistically significant difference. Conclusion: A statistically significant difference of GSTO1*A140D and GSTO2*N142D genotype distribution was detected between de novo ALL cases and controls. Compared to the control group, the MAF of GSTO1*A140D-A was overexpressed in de novo ALL cases and that of GSTO2*N142D-G was significantly higher in ALL patients. These findings suggest that the studied polymorphisms might play a significant role in the susceptibility to de novo childhood ALL in Egypt; however, GSTO1*A140D and/or GSTO2*N142D polymorphisms have no impact on ALL prognosis.

14 September 2026 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
JZJing Zhou
Jing Zhou
MYMarianne E. Yassa
Marianne E. Yassa
DYDelaney Yu
Delaney Yu
HBHector Chavarria Bernal
Hector Chavarria Bernal
Uterine carcinosarcoma is a rare and highly aggressive malignancy characterized by biphasic epithelial and mesenchymal components. Although molecular classification has improved risk stratification in endometrial carcinoma, the mutational profile of carcinosarcoma by heterologous versus homologous sarcomatous component is not well characterized. We performed a retrospective review of 27 cases diagnosed between January 2021 and June 2025. Most patients were postmenopausal women (median age, 67 yr), with a predominance of African American patients (20/27, 74.1%), and 16 of 27 (59.3%) presented with FIGO stage I–II disease. Twenty-five tumors (92.6%) were classified as p53-abnormal and 2 (7.4%) as mismatch repair-deficient. TP53 alterations predominated and were accompanied by recurrent mutations involving genes associated with cell cycle regulation, PI3K-RTK-RAS signaling, DNA damage repair, and chromatin remodeling, highlighting molecular heterogeneity within a shared p53-abnormal background. Nineteen tumors exhibited homologous and eight heterologous sarcomatous differentiation; all but one case had a serous epithelial component. Homologous tumors demonstrated a higher disease-specific mortality rate (57.9% vs. 12.5%) and significantly shorter disease-specific survival than heterologous tumors (log-rank P =0.041), whereas progression-free survival showed a similar trend ( P =0.057). Despite the predominance of early-stage disease, survival outcomes remained poor.

20 September 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
MBMohammad Barouqa
Mohammad Barouqa
MYMarianne E. Yassa
Marianne E. Yassa
NCNestor Dela Cruz
Nestor Dela Cruz
MBMaha Babker
Maha Babker
Anticoagulant therapy has undergone substantial evolution over the past century, progressing from early parenteral agents such as heparin to vitamin K antagonists (VKAs) and, more recently, to direct oral anticoagulants (DOACs). This review provides an overview of the major classes of anticoagulants, including unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, direct thrombin inhibitors, VKAs, and DOACs, with emphasis on their mechanisms of action, clinical applications, laboratory monitoring, and reversal strategies. While UFH remains widely used in acute settings, its unpredictable pharmacokinetics and risk of heparin induced thrombocytopenia have led to increased use of LMWH and fondaparinux. VKAs, historically the cornerstone of oral anticoagulation, are limited by variable dosing requirements and the need for routine monitoring. In contrast, DOACs have transformed anticoagulation management through predictable pharmacokinetics, fixed dosing, and improved safety profiles, and are now first line therapies for several thromboembolic conditions. The development of targeted reversal agents, including protamine, vitamin K, prothrombin complex concentrates, idarucizumab, and andexanet alfa, has significantly enhanced the safety of anticoagulant therapy in the setting of major bleeding or urgent procedures. Laboratory assessment remains critical for selecting anticoagulants and evaluating clinical scenarios, with evolving roles for anti-Xa assays, thrombin-based assays, and mass spectrometry techniques. Emerging anticoagulants targeting factors XI, XII, and XIII represent a promising future direction with the potential to further reduce bleeding risk while maintaining efficacy. Overall, continued advances in anticoagulant pharmacology, monitoring, and reversal strategies are driving a shift toward safer and more individualized patient care.